Home World News Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical Progression... World News Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical Progression in Patients with Metastatic Hormone-Sensitive Prostate Cancer By Ogkologos - May 27, 2025 385 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a post-hoc analysis of the ENZAMET study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR A Combination of Tucatinib and Trastuzumab Demonstrates Activity and Favourable Tolerability... October 9, 2023 Prospective Evaluation of Benefit in Patients with Advanced Cancer Treated with... February 8, 2023 Women Diagnosed with Early Breast Cancer Since 2000 Have About a... October 24, 2024 Learning to Advocate for Yourself – An Important Skill! June 15, 2023 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate Breast Cancer Patient Does Head-Shaving Photo Shoot in Hopes of Inspiring... Treatment in Breast Cancer Patients Over 70 May Be Safely Reduced Bringing the Cancer Community Back Together at ASCO Annual Meeting: Why...
